3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
258
Sarcoma
69
Dermatologic
41
Endocrine
24
Thoracic
23
Gastrointestinal
22
NET
12
Lymphoid
11
Breast
9
Gynecologic
5
Other solid neoplasm
4
Genitourinary
3
Tumor-Agnostic
2
Other hematologic neoplasm
2
Myeloid
1
Head & Neck
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
143
fludarabine phosphate
130
Busulfan
109
Tacrolimus
94
fludarabine
93
Mycophenolic Acid
90
Whole-Body Irradiation
84
Peripheral Blood Stem Cell Transplantation
81
Imatinib Mesylate
69
Antilymphocyte Serum
67
Cyclosporine
66
Azacitidine
64
Cytarabine
63
Methotrexate
60
Melphalan
60
Filgrastim
50
Granulocyte Colony-Stimulating Factor
40
Decitabine
40
Thiotepa
38
thymoglobulin
34
Stem Cell Transplantation
34
Dasatinib
34
Radiotherapy
33
nilotinib
31
ruxolitinib
28
Cord Blood Stem Cell Transplantation
28
venetoclax
26
Clofarabine
25
Specimen Handling
24
Methylprednisolone
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Temozolomide
×
Myeloid
×
Clear all
NCT00687323
2017-06-07
TALL
Merck Sharp & Dohme LLC
Phase 2
Completed
47 enrolled
12 charts